AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Relay Therapeutics, Inc.
Video analysis: RLAY
All videosNo video analysis for this stock yet. Request one from our team.
News: RLAY
Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
Allianz Asset Management GmbH Makes New $750,000 Investment in Relay Therapeutics, Inc. $RLAY
Allianz Asset Management GmbH acquired a new stake in Relay Therapeutics, Inc. (NASDAQ: RLAY) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 40,100 shares of the company's stock, valued at approximately $750,000. Other large investors have also recently made changes
Frazier Life Sciences Management L.P. Takes $19 Million Position in Relay Therapeutics, Inc. $RLAY
Frazier Life Sciences Management L.P. acquired a new position in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,015,693 shares of the company's stock, valued at approximately $19,004,000. Frazier Life Sciences
Relay Therapeutics CFO Sells 17,717 Shares for $350,000
The sale had an approximate value of nearly $350,000. The transaction reduced the executive's direct equity position by 11%.
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:
Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE
Bank of America Corp DE raised its stake in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) by 86.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,937,695 shares of the company's stock after purchasing an additional 896,746 shares during the
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.41 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.41 per share a year ago.
